TRIM21 and interstitial lung disease: The co-presence of anti-Ro52 (SSA) antibodies has repeatedly been reported to be enriched in ILD and RP-ILD patients [41,42], confirming the not-so-benign profile of this antibody in the setting of autoimmune lung involvement.